3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
81
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
HER2-positive Breast Cancer
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hematologic Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Thyroid Neoplasms
1
Thrombocytosis
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma
1
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
decitabine and cedazuridine drug combination
1
apalutamide
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Risk Assessment
1
Radiotherapy
1
Preoperative Exercise
1
Opdualag
1
Nutritional Support
1
Nivolumab
1
Injections, Subcutaneous
1
Exercise
1
Ethanol
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Patient Preference
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts